At the same time, a recent observational study of 298 MASLD patients underscored the impact of genetic risk on disease progression, demonstrating that the PNPLA3 variant is linked to elevated aspartate aminotransferase levels [21]. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.